Trelegy is a once-daily, single-inhaler triple therapy used for the long-term maintenance treatment of asthma in adults [1]. It combines fluticasone furoate, umeclidinium, and vilanterol [1]. Fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta2-adrenergic agonist (LABA) [1]. This combination targets inflammation, relaxes airway muscles, and helps to keep airways open [2].
What is Trelegy prescribed for?
Trelegy is indicated for patients with asthma who are not adequately controlled on a combination of an ICS and a LABA, or on an ICS alone [1]. It is intended as a replacement therapy for patients already taking fluticasone furoate and vilanterol, or fluticasone furoate and umeclidinium [1].
How does Trelegy work for asthma?
The ICS component, fluticasone furoate, reduces airway inflammation. The LAMA component, umeclidinium, works by blocking the action of acetylcholine on muscarinic receptors in the airways, leading to bronchodilation. The LABA component, vilanterol, stimulates beta2-adrenergic receptors in the smooth muscle of the airways, causing relaxation and further bronchodilation [1]. Together, these mechanisms help to improve lung function and reduce the frequency of asthma exacerbations [2].
When did Trelegy become available for asthma?
Trelegy Ellipta was first approved by the U.S. Food and Drug Administration (FDA) for asthma in December 2017 [1].
What are the potential side effects of Trelegy?
Common side effects associated with Trelegy may include nasopharyngitis, headache, and bronchitis [1]. Other potential side effects can include oral candidiasis, pneumonia, back pain, abdominal pain, and diarrhea [1]. Trelegy should not be used for acute asthma symptoms, such as sudden or severe breathing problems [1].
What is the dosage for Trelegy?
The recommended dosage for Trelegy for asthma is one inhalation once daily [1].
How does Trelegy compare to other asthma medications?
Trelegy offers the convenience of a single inhaler for three different medication classes, which may improve adherence for some patients. Other asthma treatment options include monotherapy with an ICS, or combinations of ICS with a LABA or LAMA. The choice of medication depends on the severity of asthma and individual patient needs [2].
Can Trelegy be used for COPD?
Trelegy is also approved for the maintenance treatment of COPD in adults [3]. It is important to distinguish between the indications, as Trelegy's use for asthma and COPD involves different approved regimens and patient populations [1, 3].
What is the patent status for Trelegy?
Information on the patent status and expiry dates for Trelegy can be found on DrugPatentWatch.com [4]. Patents for medications are crucial for determining when generic versions may become available.
Where can I find more information about Trelegy?
More detailed information, including prescribing information, can be found on the manufacturer's website or through resources like DrugPatentWatch.com [1, 4].
---
Sources:
[1] GlaxoSmithKline. (n.d.). TRELEGY ELLIPTA® (fluticasone furoate, umeclidinium, and vilanterol) inhalations powder. Retrieved from https://www.trelegy.com/
[2] DrugPatentWatch. (n.d.). Trelegy Asthma. Retrieved from https://drugpatentwatch.com/trelegy-asthma
[3] GlaxoSmithKline. (n.d.). TRELEGY ELLIPTA® (fluticasone furoate, umeclidinium, and vilanterol) inhalations powder. Retrieved from https://www.trelegycopd.com/
[4] DrugPatentWatch. (n.d.). Trelegy. Retrieved from https://drugpatentwatch.com/trelegy